Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA Grants Orphan Drug Designation for Cannabidiol in the Prevention of Ischemia and Reperfusion Injury from Organ Transplantation
FDA Grants Orphan Drug Designation for Cannabidiol in the Prevention of Ischemia and Reperfusion Injury from Organ Transplantation
FDA Grants Orphan Drug Designation for Cannabidiol in the Prevention of Ischemia and Reperfusion Injury from Organ Transplantation
Submitted by
admin
on November 7, 2018 - 10:11am
Source:
CP Wire
News Tags:
Revive Therapeutics
organ transplantation
Cannabidiol
CBD
Headline:
FDA Grants Orphan Drug Designation for Cannabidiol in the Prevention of Ischemia and Reperfusion Injury from Organ Transplantation
snippet:
The FDA also previously granted orphan drug designation for cannabidiol in the treatment of autoimmune hepatitis
Revive is developing cannabinoid pharmaceuticals to treat rare inflammatory conditions and liver disease
Do Not Allow Advertisers to Use My Personal information
